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Abstract: Background/Objectives: The diagnosis of early-stage pancreatic 
ductal adenocarcinoma (PDAC) is still challenging. We conducted a 
multicenter study to clarify the clinical features of early-stage PDAC in 
Japan.  Methods: We collected patients with stage 0 and stage I PDAC 
according to the sixth edition of the Japanese Classification of 
Pancreatic Carcinoma. We retrospectively analyzed the clinical profiles 
including opportunities for medical examination, imaging modalities and 
findings, methods of cytological diagnosis, and prognosis according to 
the stages at diagnosis. Results: Two hundred cases with Stage 0 and 
stage I PDAC were reported from 14 institutions, which accounted for 
approximately 0.7% and 3% of all PDAC cases, respectively. Overall, 20% 
of the early-stage PDAC cases were symptomatic. Indirect imaging findings 
such as dilatation of the main pancreatic duct were useful to detect 
early-stage PDAC. In particular, local fatty changes may be specific to 
early-stage PDAC. For preoperative pathologic diagnosis, cytology during 
endoscopic retrograde cholangiopancreatography was more commonly applied 
than endoscopic ultrasound fine-needle aspiration. Although the overall 
prognosis was favorable, new PDAC lesions developed in the remnant 
pancreas in 11.5% cases. Conclusions: This multicenter study revealed 
several key points concerning the diagnosis and management of early-stage 
PDAC, including screening of asymptomatic cases, importance of indirect 
imaging findings, application of cytology during endoscopic retrograde 
cholangiopancreatography, and the risk of carcinogenesis in the remnant 
pancreas. 
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Dear Editor: 
Please find enclosed our manuscript entitled “Diagnosis of pancreatic ductal adenocarcinoma in Japan,” 
which we request you to consider for publication as an Original Article in Panreatology. 
Pancreatic ductal adenocarcinoma (PDAC) has been increasing in incidence recently; however, its 
prognosis could not be improved despite further research and advancement in imaging modalities. This 
study aimed to determine the clinical features of such patients and clarified several points such as the 
need to screen high-risk asymptomatic cases, identification of indirect imaging findings, importance of 
ERCP in screening, and the risk of carcinogenesis in the remnant pancreas. Clinical data of 200 patients 
with stage 0 and 1 PDAC were collected. For early-stage PDAC, endoscopic retrograde 
cholangiopancreatography was more commonly used than endoscopic ultrasound fine-needle aspiration 
for preoperative pathologic diagnosis. We found that in 14.5% of the patients, new PDAC in the 
postoperative remnant pancreas was observed. We conclude that the findings of this study will contribute 
to the early detection and improvement of prognosis of PDAC patients. 
We believe that the findings of this study are relevant to the scope of your journal and will be of interest 
to its readership. We have approved the manuscript and agree with submission to Panreatology. There are 
no conflicts of interest to declare. 
This manuscript has not been published elsewhere and is not under consideration by another journal. We 
have already reported some of results using a part of the cases in this study in Japanese literature. 
However, we added the number of cases and showed the new findings of characteristics between Stage 0 
and I. The manuscript has been carefully reviewed by an experienced editor whose first language is 
English and who specializes in editing papers written by scientists whose native language is not English. 
We look forward to hearing from you at your earliest convenience. 
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Division of Gastroenterology, Tohoku University Graduate School of Medicine 
1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574 Japan 
Phone No: +81-22-717-7171 
Fax No: +81-22-717-7177 
Email Address: atsushih@med.tohoku.ac.jp  
 
 
 
Disclosure of Conflict of Interest Form 
 
All authors disclosed no financial relationships relevant to this publication. 
*Conflict of Interest Form
1 
 
October 21, 2017 
 
Professor Minoti Apte, 
Editor-in-Chief, Pancreatology, 
Director, Pancreatic Research Group,  
South Western Sydney Clinical School,  
University of New South Wales,  
Sydney, Australia 
 
Re: PAN-D-17-00207 
 
Dear Professor Apte, 
 
Thank you very much for your kind and helpful comments. Attached please find our 
revised manuscript entitled “Multicenter study of early pancreatic cancer in Japan", 
which we would like to submit for publication in Pancreatology. 
 
After checking the original version again, we have still found that several descriptions 
were ambiguous and some statistical figures were a little bit old. We therefore have 
revised the text more clearly, concisely and updated to increase scientific merits of this 
paper. In addition, because this paper deals with not only diagnosis but prognosis, we 
have revised the title to “Multicenter study of early pancreatic cancer in Japan”. 
 
We have carefully checked the reviewers’ helpful and constructive comments, and the 
substantial issues raised have been addressed as follows. 
 
To the Reviewer 1 
This is a very interesting paper with huge potential from a relatively large cohort of 
patients with "early stage PDAC". This paper should be considered for publication after 
revisions. 
 
-Thank you very much for your favorable comments. 
 
1. The authors need to report in further detail the preop imaging tests and their 
diagnostic value (extract some the data from table and describe in results section). 
 
-As suggested, we have described the preoperative imaging tests and their 
diagnostic value more in detail, with some data included in the text (page 9, 2
nd
 
paragraph, page 10, 1
st
 paragraph, and Table 3). 
 
*Detailed Response to Reviewers
2 
 
2. In the methodology: Expanding on 1 they should also report on their indications for 
surgery based on each of these tests especially for stage 0. For example what 
feature on MRI or ERCP cytology or EUS FNA would prompt them to operate on 
these patients. They should report in further detail why these patients underwent 
surgery especially for stage 0. 
 
-Thank you for the important suggestion. Out of 200 patients included in this study, 125 
(52.5%) patients underwent resection because malignancy was confirmed by cytology 
prior to resection. In the remaining 75 patients, decision of resection was made after 
informed consent with high suspicion of PDAC based on abnormal imaging findings, 
especially MPD dilatation and stenosis on multiple modalities. Pancreatic tumors were 
seldom detected by imaging modalities in stage 0 cases. These points are now stated in 
page 9, last paragraph, page 10, 1
st
 and 2
nd
 paragraphs. 
 
3. A table for stage 0 patients should be made showing the tests performed CT MRCP 
ERCP EUS PET and clearing stating which were "positive" resulting in the need 
for surgery  
 
-As suggested, we have stratified the number of positive imaging findings based on 
stages (stage 0 and stage 1) in Table 3.  
 
4. The number of tests which were "positive" should also be reported. For example  
30 patients had 3 preop test indicative of PDAC, 40 patients had 2 tests indicative 
of PDAC etc etc 
 
-Thank you for the important suggestion. We counted the number of positive imaging 
findings out of 14 assessed in this study according to the stage. The number of positive 
imaging findings was 5.5±2.5 in stage 0 cases and 7.2±2.8 in stage I cases. These points 
are now stated in page 9, last and page 10, 1
st
 paragraphs. 
 
5. Discusson: there have been some natural history papers of PANIN published in the 
literature which should be discussed especially PANIN 3 which corresponds to the 
author's stage 0. 
 
-As suggested, we have cited two papers describing the natural history of PDAC and 
PanIN (references 13 and 14), and added some description on this topic in page 12, 1
st
 
paragraph. 
 
6. Pg 10 Line 24 Please revise sentence to: The sentence implies that the study showed 
these were risk factors of early stage PDAC found in the paper (which is not true as 
3 
 
there was no comparison with the normal population). Diabetes mellitus was 
present in 64 (32%)….. 
     
-As suggested, we have revised the text accordingly (page 8, 1
st
 paragraph). 
 
To the Reviewer 2 
In their manuscript entitled "Diagnosis of early-stage pancreatic ductal 
adenocarcinoma in Japan", Kano et al. have summarized their data on Stages 0 and I 
pancreatic cancer according to the Japanese Classification of Pancreatic Carcinoma. 
This is an interesting paper and is written in a clear way.  
 
Thank you very much for your favorable comments. 
 
1. Please describe more clearly what is meant by diabetes mellitus throughout the 
paper. In the last decade it became clearer that new diagnosis of late onset (>50y) 
diabetes mellitus is a risk factor for PDAC. On the other hand DM per se, has in 
the literature, contradictory associations with PDAC. 
 
-In this study, we only asked the presence or absence of DM from the viewpoint of a 
risk factor for PDAC, and did not ask the interval of DM onset and PDAC diagnosis. 
This point is now stated in page 8, 1
st
 paragraph. 
 
2. Please clarify the association of IPMN and PDAC in P9 in 52 cases. Is this a 
coincental finding with PDAC or are the authors reporting cancer cases developing 
on the background of IPMN? If the latter is the case it contradicts their methods 
section where they exclude patients with high grade IPMN or cancer associated 
with it.  
 
-In this study, concomitant IPMN, in which PDAC developed at a site in the pancreas 
different from that of the IPMN according to the imaging and/or histologic findings, 
was regarded as a risk factor. Patients with high-grade IPMN or IPMN-derived invasive 
cancer, showing a histologic transition between IPMN and PDAC, were excluded. This 
point is now stated in page 6, 1
st
 paragraph. 
 
3. Please describe the pathologic discrimination between conincidental PDAC and 
IPMN and IPMN-rderived cancer. 
 
- In this study, concomitant IPMN, in which PDAC developed at a site in the pancreas 
different from that of the IPMN according to the imaging and/or histologic findings, 
was regarded as a risk factor. Patients with high-grade IPMN or IPMN-derived invasive 
4 
 
cancer, showing a histologic transition between IPMN and PDAC, were excluded. This 
point is now stated in page 6, 1st paragraph. 
 
4. Please describe the study period 
 
-As suggested, we have clearly stated the study period (page 6, 1
st
 paragraph). 
 
5. Please describe the pathological findings of Stage0 and 1a and 1b cancers 
according to TNM classification as well and compare differences. Please also 
report the dimensions of stage 0 cancers in mm (mean, median,range) 
 
-As stated in page 6, 1
st
 paragraph, stages were determined according to the according 
to the sixth edition of the Japanese Classification of Pancreatic Carcinoma [reference 
#9]. Early-stage PDAC were defined as cases with stage 0 (high-grade pancreatic 
intraepithelial neoplasia (PanIN)/carcinoma in situ) and stage I (invasive carcinoma 
with tumor diameter of <20 mm confined within the pancreas, along with no regional 
lymph node metastasis (N0) and distant metastasis (M0)). Stage I cases were further 
classified as stage I (TS1a) (tumor size <10 mm) and stage I (TS1b) (tumor size 11-20 
mm) based on the tumor size in largest diameter [reference #5]. Stage 0 PDAC defined 
by the Japanese classification are similar to that diagnosed by UICC classification. 
Stage I PDAC is defined as the tumor limited to the pancreas with dimension of 2 cm or 
less. On the other hand, as per the UICC classification, stage I PDAC includes tumor 
limited to the pancreas of any size. The definition of staging is now clearly stated in 
page 6, 1
st
 paragraph. 
 
6. Were there any patients that refused operation and folowed up despite suggestive 
findings for stage 0 cancer. Please comment on their follow-up and prognosis. 
 
-We have no information about such cases. 
 
7. p13 please explicitly write that asymptomatic patients should be examined UPON 
INCIDENTAL FINDING OF MPD dilatation etc. Otherwise it will be an 
overstatement to suggest examining asymptomatic patients 
 
-As suggested, we now clearly state that “Subjects with the risk factors, especially those 
with multiple risk factors, should be advised to undergo further medical examination if 
such findings are detected.”(page 13, last paragraph) 
 
8. Please comment on the follow-up duration of pts after pancreatic resection, 
methods and its cost-effectiveness. 
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-Thank you very much for pointing out the important issue. For the postoperative 
surveillance, the NCCN Clinical Practice Guidelines [reference #25] recommend a 
history and physical examination for symptom assessment every 3 to 6 months for 2 
years, then every 6 to 12 months. CA 19-9 level testing and follow-up 
contrast-enhanced CT scans every 3 to 6 months for 2 years after surgical resection. The 
Japanese Guideline [reference #8] suggests tumor marker assessment and follow-up 
contrast-enhanced CT scans every 3 to 6 months for 2 years, then every 6 to 12 months 
at least for 5 years after surgical resection. Because the prognosis of patients with 
early-stage PDAC is much more favorable than the general PDAC cases, 
cost-effectiveness is another important issue for the long-term surveillance after 
resection [reference #26]. These points are now stated in page 14, 2
nd
 paragraph. 
 
We hope that our paper is now acceptable for publication in Pancreatology. 
 
Very Sincerely, 
 
 
 
 
Atsushi Kanno, M.D., Ph.D., and Atsushi Masamune, M.D., Ph.D. 
 
Division of Gastroenterology,  
Tohoku University Graduate School of Medicine, 
1-1 Seiryo-machi, Aoba-ku, 
Sendai 980-8574 JAPAN 
tel, 81-22-717-7172; fax, 81-22-717-7177 
e-mail: atsushih@med.tohoku.ac.jp 
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Abbreviations used are: CT, computed tomography; DM, diabetes mellitus; ENPD, 
endoscopic nasopancreatic duct drainage; ERCP, endoscopic retrograde 
cholangiopancreatography; EUS, endoscopic ultrasonography; FDG-PET, 
18
F-fluorodeoxyglucose-positron emission tomography; FNA, fine needle aspiration; IPMN, 
intraductal papillary mucinous neoplasm; MPD, main pancreatic duct; MRI, magnetic 
resonance imaging; PDAC, pancreatic ductal adenocarcinoma; US, ultrasonography. 
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Abstract 
Background/Objectives: The diagnosis of early-stage pancreatic ductal adenocarcinoma 
(PDAC) is still challenging. We conducted a multicenter study to clarify the clinical features 
of early-stage PDAC in Japan.  Methods: We collected patients with stage 0 and stage I 
PDAC according to the sixth edition of the Japanese Classification of Pancreatic Carcinoma. 
We retrospectively analyzed the clinical profiles including opportunities for medical 
examination, imaging modalities and findings, methods of cytological diagnosis, and 
prognosis according to the stages at diagnosis. Results: Two hundred cases with Stage 0 and 
stage I PDAC were reported from 14 institutions, which accounted for approximately 0.7% 
and 3% of all PDAC cases, respectively. Overall, 20% of the early-stage PDAC cases were 
symptomatic. Indirect imaging findings such as dilatation of the main pancreatic duct were 
useful to detect early-stage PDAC. In particular, local fatty changes may be specific to 
early-stage PDAC. For preoperative pathologic diagnosis, cytology during endoscopic 
retrograde cholangiopancreatography was more commonly applied than endoscopic 
ultrasound fine-needle aspiration. Although the overall prognosis was favorable, new PDAC 
lesions developed in the remnant pancreas in 11.5% cases. Conclusions: This multicenter 
study revealed several key points concerning the diagnosis and management of early-stage 
PDAC, including screening of asymptomatic cases, importance of indirect imaging findings, 
application of cytology during endoscopic retrograde cholangiopancreatography, and the 
risk of carcinogenesis in the remnant pancreas. 
 
Keywords: diabetes mellitus; endoscopic retrograde cholangiopancreatography; intraductal 
papillary mucinous neoplasm; pancreatic ductal adenocarcinoma 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic 
cancer, which is a lethal malignancy with very high mortality rates [1]. The American 
Cancer Society estimates that 53,670 (27,970 men and 25,700 women) cases will be 
diagnosed as having pancreatic cancer and 43,090 (22,300 men and 20,790 women) deaths 
will be caused by pancreatic cancer in 2017 [2]. According to the Vital Statistics Japan 
reported by the Ministry of Health, Labour and Welfare 
(http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/suikei15/) [3], pancreatic cancer is the 
fourth leading cause of cancer-related death and the mortality rate was 26.5 per 100,000 men 
and 24.4 per 100,000 women in 2015 in Japan.  
It has been increasingly recognized that the prognosis of patients with early-stage 
pancreatic cancer is favorable [4, 5]. The Japan Pancreatic Cancer Registry showed that the 
5-year survival rates of patients with the Union for International Cancer Control (UICC) 
stage 0 (in situ), stage IA and stage IB were 85.8%, 68.7%, and 59.7%, respectively [5]. 
However, the corresponding proportions of stages 0, IA, and IB cases accounted for only 
1.7%, 4.1%, and 6.3%, respectively. The 5-year survival rate of cases with PDAC smaller 
than 10 mm (TS1a) reached 80.4%, but this accounts for only 0.8% of all PDAC cases [5]. 
These figures indicate that the early diagnosis of pancreatic cancer is a great challenge [4]. 
There are several reasons for the difficulties in the early diagnosis of pancreatic cancer 
including the absence of early-stage biomarkers, anatomical location in the retroperitoneum 
allowing invasion to the surrounding organs and blood vessels, and non-specific symptoms 
[6, 7]. Several risk factors for PDAC have been identified including intraductal papillary 
mucinous neoplasm (IPMN) and diabetes mellitus (DM) [8]. However, no effective strategy 
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 5 
for using these risk factors to detect early pancreatic cancer has been established. 
In 2014, the Japan Study Group on the Early Detection of Pancreatic Cancer was 
established to clarify the clinical, imaging, and pathological characteristics of early-stage 
PDAC cases. We here report the results of a multicenter study to clarify the characteristic 
features of early-stage PDAC cases in Japan. 
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Methods 
This was a retrospective, observational study that examined the clinic-pathologic 
features of patients with early-stage PDAC diagnosed between January 2006 and December 
2015 at 14 participating institutions that comprised the JEDPAC. The stage of PDAC was 
determined histopathologically by resection according to the sixth edition of the Japanese 
Classification of Pancreatic Carcinoma [9]. Early-stage PDAC were defined as cases with 
stage 0 (high-grade pancreatic intraepithelial neoplasia (PanIN)/carcinoma in situ) and stage I 
(invasive carcinoma with tumor diameter of <20 mm confined within the pancreas, along with 
the absence of regional lymph node metastasis (N0) and distant metastasis (M0)). Stage I 
cases were further classified as stage I (TS1a) (tumor size <10 mm) and stage I (TS1b) (tumor 
size 11-20 mm) based on the tumor size in largest diameter [5]. The pathologic assessment of 
cases was left to the discretion of each institution. Concomitant IPMN, in which PDAC 
developed at a site in the pancreas different from that of the IPMN according to the imaging 
and/or histologic findings [10], was regarded as a risk factor. Patients with high-grade IPMN 
or IPMN-derived invasive cancer, showing a histologic transition between IPMN and PDAC, 
were excluded. Some patients included in this study were reported in our previous review in 
Japanese [11]. 
The following information was sent to the data center at Tohoku University Graduate 
School of Medicine after linkable anonymization: (i) clinical backgrounds (age, gender, 
absence or presence of risk factors for PDAC, etc.); (ii) opportunities for medical examination 
for early-stage PDAC (check-up, symptomatic or asymptomatic, incidental detection during 
screening for other diseases); (iii) imaging modalities used for the diagnosis; (iv) imaging 
findings on abdominal ultrasonography (US), computed tomography (CT), magnetic 
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 7 
resonance imaging (MRI), endoscopic ultrasonography (EUS), endoscopic retrograde 
cholangiopancreatography (ERCP), and 
18
F-fluorodeoxyglucose-positron emission 
tomography (FDG-PET); (v) the methods for the cytological diagnosis of early-stage PDAC 
(ERCP or EUS-fine needle aspiration (FNA)); and (vi) prognosis. 
All analyses were performed using JMP software (version 9.0.2; SAS Institute, 
Chicago, IL, USA). Continuous variables were compared using Student’s t test. Chi-square 
test or Fisher's exact test was appropriately used for the comparison of proportions. The 
Kaplan–Meier survival analysis was used to compare the overall survival according to the 
stage. This study was approved by the institutional review boards of all participating 
institutions. 
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Results 
Clinical characteristics of early-stage PDAC 
In the 14 participating institutions, 6942 cases with PDAC were diagnosed and 2647 
cases underwent resection during the study period. There were 51 stage 0 and 149 stage I 
cases accounting for 0.7% and 2.3% of the all PDAC cases, respectively. Of the 200 cases 
with stage 0 and I PDAC, there were 109 men and 91 women, with an average age of 68.8 
years (range, 39-88 years). The average observation period was 1240.8 days (range, 66–3635 
days). PDAC was located in the pancreatic head in 86 (43%) cases, in the pancreatic body in 
103 (51.5%) cases, and in the pancreatic tail in only 11 (5.5%) cases. One hundred thirty nine 
(69.5%) cases had at least one risk factor. DM was present in 64 (32.0%), smoking in 62 
(31.0%), and IPMN in 52 (26.0%) cases. We only inquired about the presence or absence of 
DM, but did not ask about the interval of DM onset and PDAC diagnosis. The clinical 
characteristics were not different between stage 0 and I cases (data not shown). 
 
Opportunities for detection of early-stage PDAC 
Early-stage PDAC was detected by further medical examination due to the presence 
of symptoms in 50 cases (25.0%): abnormalities on medical check-up in 34 (17.0%) and 
abnormalities during examination or follow-up for other diseases in 103 (51.5%). The 
patients presented with the following symptoms: abdominal pain in 36 (72.0%), back pain in 
13 (26.0%), nausea in 4 (8.0 %), diarrhea in 1 (2.0%), and jaundice in 1 (2.0%). Of the 34 
patients in whom abnormalities were detected during medical check-up, 31 (91.2%) were 
detected by US, whereas only 1 (2.9%) case presented with an elevation of tumor marker 
levels. The abnormal findings detected by US were dilatation of the main pancreatic duct 
(MPD) in 21 (67.7%) cases, direct detection of a tumor in 9 (29.0%), and stenosis of the 
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 9 
MPD in 1 (3.2%). Among the 103 patients in whom an abnormality was incidentally 
detected during examination or follow-up for other diseases, 99 (96.1%) cases had abnormal 
imaging findings on CT (n=49; 49.5%) and US (n=41; 41.4%). Cases with elevated 
pancreatic enzyme and tumor marker levels were rare. No stage 0 PDAC case presented with 
elevated tumor markers. 
 
Imaging modalities for diagnosis of early-stage PDAC 
Several imaging modalities were used for the diagnosis of early-stage PDAC; in 
particular, CT, MRI, and EUS were performed in most cases (Table 3). Abnormal US 
findings included MPD dilatation in 101/135 (74.8%) cases, MPD stenosis in 27/135 (20.0%), 
and tumor detection in 71/135 (52.6%). Abnormal CT findings were MPD dilatation in 
156/196 (79.6%) cases, tumor detection in 101/196 (51.5%), and local fatty changes in 82/196 
(41.8%) (Fig. 1). Abnormal MRI findings included MPD dilatation in 143/173 (82.7%) cases 
and tumor detection in 78/173 (45.1%). Abnormal findings on EUS were MPD dilatation in 
153/173 (88.4%) cases, MPD stenosis in 98/173 (56.6%), and tumor detection in 132/173 
(76.3%). ERCP was performed after informed consent in 141 (70.5%) cases and revealed 
MPD dilatation in 114/141 (80.9%) and MPD stenosis in 112/141 (79.4%) cases. FDG-PET 
was performed in 61 (30.5%) cases and FDG accumulation was seen in 1/11 stage 0 and 30/50 
(60.0%) stage I cases. We compared the number of positive imaging findings out of 14 
assessed in this study (MPD dilatation, MPD stenosis, and pancreatic tumors on US; MPD 
dilatation, pancreatic tumors, and local fatty changes of parenchyma on CT; MPD dilatation 
and pancreatic tumors on MRI; MPD dilatation, MPD stenosis, and pancreatic tumors on 
EUS; MPD dilatation and MPD stenosis on ERCP, and FDG accumulation on FDG-PET) 
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between stage 0 and I cases. The number of positive imaging findings was significantly lower 
in stage 0 (5.5±2.5,  mean±standard deviation) cases than in stage I cases (7.2±2.8) (P<0.01).  
Of note, pancreatic tumors were seldom detected by imaging modalities in stage 0 cases. 
 
Cytological diagnosis of early-stage PDAC 
Cytology is important for histologic confirmation of PDAC. Malignancy was 
confirmed by cytology prior to resection in 125 (62.5%) cases. In the remaining 75 (37.5%) 
cases, decision of resection was made after informed consent with high suspicion of PDAC 
based on abnormal imaging findings, especially MPD dilatation on multiple modalities. If 
stratified by stage, 27/51 (52.9%) stage 0 cases and 98/141 (65.8%) stage 1 cases underwent 
resection after the confirmation of malignancy. Most (26/27; 96.3%) of the stage 0 cases 
were diagnosed using pancreatic juice obtained by endoscopic nasopancreatic duct drainage 
(ENPD) and only one case was diagnosed by EUS-FNA (Table 4). Six stage 0 cases were 
also diagnosed by brushing cytology. In the stage 1 cases, 24 were diagnosed by brushing 
cytology, 29 using the pancreatic juice obtained by ENPD, and 53 by EUS-FNA. The 
proportion of malignancy by EUS-FNA was higher in stage 1 (53/63; 84.1%) than in stage 0 
(1/6; 16.7%) (P=0.001).  
 
Prognosis 
Figure 3 shows the Kaplan–Meier estimates of the overall survival according to the 
stages. The estimated overall survival rates at 10 years after the resection for stage 0, stage I 
(TS1a), and stage I (TS1b) were 94.7%, 93.8%, and 78.9%, respectively (Fig. 2). Although 
the difference was not statistically significant, overall survival rates tended to be lower in the 
Stage I (TS1b) cases (P=0.07 vs. stage 0 cases and P=0.20 vs. stage I (TS1a) cases). Of note, 
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new PDAC lesions were detected in the remnant pancreas in 31 cases (15.5%) (Fig. 3). 
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Discussion 
The prognosis of PDAC has not improved despite extensive research and advances in 
imaging modalities. PDAC develops through a stepwise progression from precursor lesions 
including PanIN [12]. PanIN originates in small terminal pancreatic ducts [13]. Using a 
mathematical model, Yachida et al. [14] estimated a period of 11.7 years on average from the 
initiation of pancreatic tumorigenesis until the birth of the founder cell of a parental clone, 
6.8 years until the birth of the cell giving rise to the index lesion, and 2.7 years until the death 
of the patient. Theoretically, there is a chance to diagnose early-stage PDAC, but it is a great 
challenge in daily practice [6, 7]. We here reported the clinical characteristics of 200 patients 
with early-stage PDAC. Only 25% cases were symptomatic, indicating the importance of 
surveillance in asymptomatic subjects. There is a consensus that screening of PDAC should 
be performed within high-risk groups but not within the general population [15, 16]. There 
are several risk factors for PDAC including a family history of pancreatic cancer or 
hereditary pancreatic cancer syndrome, hereditary pancreatitis, DM, obesity, chronic 
pancreatitis, IPMN, pancreatic cysts, smoking, and alcohol consumption [8]. In this study, 
about 70% of the patients had at least one risk factor, with DM as the most common. An 
association between new-onset DM and pancreatic cancer has been established [17], but it 
remains unknown whether new-onset DM is associated with early-stage PDAC. The large 
number of patients with new-onset DM is an obstacle to developing an efficient screening 
system.  
Several reports have described strategies for the surveillance of high-risk groups. 
Canto et al. [15] demonstrated the diagnostic utility of EUS and MRI in high-risk patients 
with hereditary pancreatic cancer syndrome and a family history of PDAC. Harinck et al. 
[18] reported the complementary roles of EUS and MRI in detecting pancreatic lesions in 
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such patients. Kamata et al. [19] reported that semiannual EUS was superior to annual US, 
CT or MRI for detecting concomitant PDAC during the follow-up of patients with IPMN. 
These reports confirm the utility of EUS in detecting PDAC in subjects at high risk. 
However, the number of facilities that can perform EUS routinely is still limited even in 
Japan and multiple EUS sessions per year for all IPMN cases are not realistic in the clinical 
setting.   
 Malignancy was confirmed by cytology prior to resection in 125 (62.5%) cases. 
Unlike PDAC cases in general, EUS-FNA was not useful for the preoperative diagnosis of 
malignancy in stage 0 cases, because the tumor could not be directly detected. Most of the 
stage 0 cases were diagnosed using pancreatic juice obtained by ENPD. Repeated pancreatic 
juice cytology using ENPD revealed that serial pancreatic juice aspiration cytological 
examination could be a feasible method for the diagnosis of pancreatic carcinoma in situ [20]. 
On the other hand, the remaining 75 (37.5%) cases underwent resection despite the absence 
of preoperative confirmation of malignancy. In these cases, the decision for resection was 
made with a high suspicion of PDAC based on abnormal imaging findings. Many imaging 
modalities are utilized during the diagnostic process of early-stage PDAC. Cases with stage 
0 presented with fewer imaging findings than stage I cases, mainly due to the difficulty in the 
actual identification of tumors in stage 0 cases. Our results underscored the importance of 
indirect imaging findings for detecting early-stage PDAC in asymptomatic cases. The 
relatively low proportion of cases in the pancreatic tail (5.5%) might reflect the rarity of 
developing MPD dilatation due to the relatively small volume upstream of the tumor. 
Subjects with the risk factors, especially those with multiple risk factors, should be advised 
to undergo further medical examination if such findings are detected. In addition to MPD 
dilatation, abnormal MPD stenosis was observed on ERCP in 83% of stage 0 cases. 
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Interestingly, local fatty changes of the pancreatic parenchyma were detected in 21/50 (42%) 
stage 0 and 61/146 (41.8%) stage I cases. The underlying mechanism for the development of 
local fatty changes remains unknown, but might involve the interaction with the surrounding 
pancreatic parenchyma [21, 22]. 
 In this study, PDAC developed in the remnant pancreas in 31 (15.5%) cases. 
Along with the previous case reports of metachronous cancer in the remnant pancreas [23, 
24], our results suggested the importance of follow-up after surgery even in patients with 
early-stage PDAC. For the postoperative surveillance, the NCCN Clinical Practice 
Guidelines [25] recommend a history and physical examination for symptom assessment 
every 3 to 6 months for 2 years, then every 6 to 12 months, and then CA 19-9 level testing 
and follow-up contrast-enhanced CT scans every 3 to 6 months for 2 years after surgical 
resection. The Japanese Guidelines [8] suggest tumor marker assessment and follow-up 
contrast-enhanced CT scans every 3 to 6 months for 2 years, then every 6 to 12 months at 
least for 5 years after surgical resection. Because the prognosis of patients with early-stage 
PDAC is much more favorable than the general PDAC cases, cost-effectiveness is another 
important issue for the long-term surveillance after resection [26].  
 In summary, this multicenter study revealed several key points in the diagnosis 
and management of early-stage PDAC, including risk factors, screening of asymptomatic 
cases, identification of indirect imaging findings, and the risk of carcinogenesis in the 
remnant pancreas. Because the number of gastroenterologists specializing in pancreatic 
cancer is rather limited, it is important that these key points be made known to general 
physicians as well and prompt them to refer suspicious cases to core hospitals for further 
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examinations [26]. Further clarification of early-stage PDAC is warranted to improve the 
prognosis of this intractable disease.  
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Figure legends 
Figure 1: A case of stage I PDAC with localized fatty changes 
a. Localized tissue atrophy and fatty changes are observed in the pancreatic tail on CT 
(arrowhead). 
b. Histologic findings reveal fatty changes in localized regions of the pancreatic 
parenchyma. 
c. High-grade PanIN/carcinoma in situ is observed in a branch of the pancreatic duct. 
 
Figure 2: Kaplan–Meier estimates of the overall survival according to the stages. 
The overall survival was calculated using the Kaplan–Meier method. Censored subjects are 
indicated on the Kaplan-Meier curve as tick marks. The overall survival rates at 10 years 
after the resection were 94.7% in stage 0 cases, 93.8% in stage I (TSIa), and 78.9% in stage I 
(TSIb). 
 
Figure 3: A case of newly developed PDAC in the remnant pancreas 
a. CT reveals a small tumor in the pancreatic body (arrow). 
b. The pancreatic tumor is detected by EUS in the pancreatic body (arrow). 
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c. At the age of 61 years, this patient underwent distal pancreatectomy, which revealed 
stage I pancreatic cancer with clear margins on pathologic examination. 
d. After four years, a new tumor was detected in the pancreatic head on CT (arrowhead). 
e. EUS revealed a hypoechoic lesion in the pancreatic head (arrowhead). 
f. This patient underwent total remnant pancreatectomy and the pathologic diagnosis was 
invasive PDAC. 
 
 1 
Table 1. Clinical characteristics of patients with stage early-stage PDAC 
 All cases 
(n = 200) 
Stage 0 cases 
(n = 51) 
Stage I cases 
(n = 149) 
Sex (male/female) 111/89 29/22 82/67 
Age, mean ± SD (range) 68.8 ± 9.5 (38–88) 69.3 ± 8.2 (52–84) 68.5 ± 9.9 (38–88) 
Observation period 
(days), median (range) 
1240.8 (66–3635) 1392.2 (73–3546) 1189.0 (66–3635) 
Location, 
head/body/tail, n (%) 
86 (43.0)/103 
(51.5)/11 (5.5) 
17 (33.3)/30 
(58.8)/4 (7.8) 
69 (46.3)/73 (49.0)/7 
(4.7) 
Risk factors, n (%)*     
 DM 64 (32.0) 13 (25.5) 51 (34.2) 
Tobacco use 62 (31.0) 20 (39.2) 42 (28.2) 
IPMN 52 (26.0) 20 (39.2) 32 (21.5) 
Chronic pancreatitis 30 (15.0) 16 (31.4) 14 (9.4) 
Heavy Alcohol 
consumption 
26 (13.0) 10 (19.6) 16 (10.7) 
Obesity 13 (6.5) 4 (7.8) 9 (6.0) 
Family history of 
pancreatic cancer 
9 (4.5) 1 (2.0) 8 (5.4) 
DM, diabetes mellitus; IPMN, intraductal papillary mucinous neoplasm; SD, standard deviation 
*: Some cases had multiple risk factors. 
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 Table 2. Opportunities for medical examination in patients with early-stage PDAC 
Examination opportunities 
All cases (%) 
(n = 200) 
Stage 0 cases (%) 
(n = 51) 
Stage 1 cases (%) 
(n = 149) 
Symptoms 50/200 (25.0) 16/51 (31.4) 34/149 (22.8) 
 
Abdominal pain 36/50 (72.0) 11/16 (68.8) 25/34 (73.5) 
Back pain 13/50 (26.0) 6/16 (37.5) 7/34 (20.6) 
Nausea 4/50 (8.0) 2/16 (12.5) 2/34 (5.9) 
Diarrhea 1/50 (2.0) 1/16 (6.3) 0/34 (0) 
Jaundice 1/50 (2.0) 1/16 (6.3) 0/34 (0) 
Other 7/50 (14.0) 2/16 (12.5) 5/34 (14.7) 
Abnormalities identified on 
medical check-up 
34/200 (17.0) 10/51 (19.6) 24/149 (16.1) 
 
Abnormal findings on US 31/34 (91.2) 10/10 (100) 21/24 (87.5) 
Findings 
MPD dilatation 21/31(67.7) 10/10 (100) 11/21 (52.4) 
MPD stenosis 1/31(3.2) 0/10 (0) 1/21 (4.8) 
Detection of 
tumor 
9/31(29.0) 0/10 (0) 9/21 (42.9) 
Other 3/31(9.7) 0/10 (0) 3/21 (14.3) 
Elevated tumor marker levels 1/34 (2.9) 0/10(0) 1/24 (4.2) 
Others 2/34 (5.9) 0/10(0) 2/24 (8.3) 
Abnormalities identified during 
screening for other disease  
103/200 (51.5) 18/51 (35.3) 85/149 (57.0) 
 Abnormal imaging 
findings 
99/103 (96.1) 17/18 (94.4) 82/85(96.5) 
 
CT 49/99 (49.5) 8/17 (47.1) 41/82 (50.0) 
US 41/99 (41.4) 6/17 (35.3) 35/82 (42.7) 
MRI 4/99 (4.0) 1/17 (5.9) 3/82 (3.7) 
ERCP 3/99 (3.0) 2/17 (11.8) 1/82 (1.2) 
EUS 1/99 (1.0) 0/17(0) 1/82 (1.2) 
Other 1/99 (1.0) 0/17(0) 1/82 (1.2) 
Elevated pancreatic 
enzymes 
6/103 (5.8) 1/18 (5.6) 5/85 (5.9) 
Elevated tumor 
marker levels 
4/103 (3.9) 0/18 (0) 4/85 (4.7) 
Other 15/200 (7.5) 8/51 (15.7) 7/149 (7.5) 
MPD, main pancreatic duct; ERCP, endoscopic retrograde cholangiopancreatography; EUS, 
endoscopic ultrasonography 
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Table 3. Imaging modalities and findings for diagnosis of early-stage PDAC 
 
Modalities and findings 
All cases (%) 
(n = 200) 
Stage 0 cases (%) 
(n = 51) 
Stage I cases (%) 
(n = 149) 
US 135/200 (67.5) 34/51 (66.7) 101/149 (67.8) 
Findings 
MPD dilatation 101/135 (74.8) 26/34 (76.5) 75/101 (74.3) 
MPD stenosis 27/135 (20.0) 2/34 (5.9) 25/101 (24.8) 
Pancreatic tumors 71/135 (52.6) 3/34 (8.8) 68/101 (67.3) 
CT 196/200 (98.0) 50/51 (98.0) 146/149 (98.0) 
Findings 
 
MPD dilatation 156/196 (79.6) 36/50 (72.0) 120/146 (82.2) 
Pancreatic tumors 101/196 (51.5) 5/50 (10.0) 96/146 (65.8) 
Focal fatty changes of 
parenchyma 
82/196 (41.8) 21/50 (42.0) 61/146 (41.8) 
MRI 173/200 (86.5) 46/51 (90.2) 127/149 (85.2) 
Findings 
MPD dilatation 143/173 (82.7) 34/46 (73.9) 109/127 (85.8) 
Pancreatic tumors 78/173 (45.1) 5/46 (10.9) 73/127 (57.5) 
EUS 173/200 (86.5) 41/51 (80.4) 132/149 (88.6) 
Findings 
MPD dilatation 153/173 (88.4) 35/41 (85.4) 118/132 (89.4) 
MPD stenosis 98/173 (56.6) 28/41 (68.3) 70/132 (53.0) 
Pancreatic tumors 132/173 (76.3) 10/41 (24.4) 122/132 (92.4) 
ERCP 141/200 (70.5) 47/51 (92.2) 94/149 (63.1) 
Findings 
MPD dilatation 114/141 (80.9) 39/47 (83.0) 75/94 (79.8) 
MPD stenosis 112/141 (79.4) 39/47 (83.0) 73/94 (77.7) 
FDG-PET 61/200 (30.5) 11/51 (21.6) 50/149 (33.6) 
 FDG accumulation 31/61 (50.8) 1/11 (9.1) 30/50 (60.0) 
MPD, main pancreatic duct; EUS, endoscopic ultrasonography; ERCP, endoscopic retrograde 
cholangiopancreatography; FDG-PET, 
18
F-fluorodeoxyglucose-positron emission tomography  
Table
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Table 4. Cytological diagnosis of early-stage PDAC 
 All cases (%) 
(n = 200) 
Stage 0 cases (%) 
(n = 51) 
Stage 1 cases (%) 
(n = 149) 
Cytology during ERCP 79/141 (56.0) 36/47 (76.6) 48/94 (51.1) 
 
Confirmation of 
malignancy 
Brush 30/62 (48.4) 6/14 (42.9) 24/43 (55.8) 
ENPD 55/79 (69.6) 26/36 (72.2) 29/48 (60.4) 
Cytology by EUS-FNA 69/200 (34.5) 6/51 (11.8) 63/149 (42.3) 
 
Confirmation of 
malignancy 
54/69 (78.3) 1/6 (16.7) 53/63 (84.1) 
ERCP, endoscopic retrograde cholangiopancreatography; ENPD, endoscopic nasopancreatic duct 
drainage; EUS-FNA, endoscopic ultrasonography-fine needle aspiration 
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Abstract 
Background/Objectives: The diagnosis of early-stage pancreatic ductal adenocarcinoma 
(PDAC) is still challenging. We conducted a multicenter study to clarify the clinical features 
of early-stage PDAC in Japan.  Methods: We collected patients with stage 0 and stage I 
PDAC according to the sixth edition of the Japanese Classification of Pancreatic Carcinoma. 
We retrospectively analyzed the clinical profiles including opportunities for medical 
examination, imaging modalities and findings, methods of cytological diagnosis, and 
prognosis according to the stages at diagnosis. Results: Two hundred cases with Stage 0 and 
stage I PDAC were reported from 14 institutions, which accounted for approximately 0.7% 
and 3% of all PDAC cases, respectively. Overall, 20% of the early-stage PDAC cases were 
symptomatic. Indirect imaging findings such as dilatation of the main pancreatic duct were 
useful to detect early-stage PDAC. In particular, local fatty changes may be specific to 
early-stage PDAC. For preoperative pathologic diagnosis, cytology during endoscopic 
retrograde cholangiopancreatography was more commonly applied than endoscopic 
ultrasound fine-needle aspiration. Although the overall prognosis was favorable, new PDAC 
lesions developed in the remnant pancreas in 11.5% cases. Conclusions: This multicenter 
study revealed several key points concerning the diagnosis and management of early-stage 
PDAC, including screening of asymptomatic cases, importance of indirect imaging findings, 
application of cytology during endoscopic retrograde cholangiopancreatography, and the 
risk of carcinogenesis in the remnant pancreas. 
 
Keywords: diabetes mellitus; endoscopic retrograde cholangiopancreatography; intraductal 
papillary mucinous neoplasm; pancreatic ductal adenocarcinoma 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic 
cancer, which is a lethal malignancy with very high mortality rates [1]. The American 
Cancer Society estimates that 53,670 (27,970 men and 25,700 women) cases will be 
diagnosed as having pancreatic cancer and 43,090 (22,300 men and 20,790 women) deaths 
will be caused by pancreatic cancer in 2017 [2]. According to the Vital Statistics Japan 
reported by the Ministry of Health, Labour and Welfare 
(http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/suikei15/) [3], pancreatic cancer is the 
fourth leading cause of cancer-related death and the mortality rate was 26.5 per 100,000 men 
and 24.4 per 100,000 women in 2015 in Japan.  
It has been increasingly recognized that the prognosis of patients with early-stage 
pancreatic cancer is favorable [4, 5]. The Japan Pancreatic Cancer Registry showed that the 
5-year survival rates of patients with the Union for International Cancer Control (UICC) 
stage 0 (in situ), stage IA and stage IB were 85.8%, 68.7%, and 59.7%, respectively [5]. 
However, the corresponding proportions of stages 0, IA, and IB cases accounted for only 
1.7%, 4.1%, and 6.3%, respectively. The 5-year survival rate of cases with PDAC smaller 
than 10 mm (TS1a) reached 80.4%, but this accounts for only 0.8% of all PDAC cases [5]. 
These figures indicate that the early diagnosis of pancreatic cancer is a great challenge [4]. 
There are several reasons for the difficulties in the early diagnosis of pancreatic cancer 
including the absence of early-stage biomarkers, anatomical location in the retroperitoneum 
allowing invasion to the surrounding organs and blood vessels, and non-specific symptoms 
[6, 7]. Several risk factors for PDAC have been identified including intraductal papillary 
mucinous neoplasm (IPMN) and diabetes mellitus (DM) [8]. However, no effective strategy 
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for using these risk factors to detect early pancreatic cancer has been established. 
In 2014, the Japan Study Group on the Early Detection of Pancreatic Cancer was 
established to clarify the clinical, imaging, and pathological characteristics of early-stage 
PDAC cases. We here report the results of a multicenter study to clarify the characteristic 
features of early-stage PDAC cases in Japan. 
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Methods 
This was a retrospective, observational study that examined the clinic-pathologic 
features of patients with early-stage PDAC diagnosed between January 2006 and December 
2015 at 14 participating institutions that comprised the JEDPAC. The stage of PDAC was 
determined histopathologically by resection according to the sixth edition of the Japanese 
Classification of Pancreatic Carcinoma [9]. Early-stage PDAC were defined as cases with 
stage 0 (high-grade pancreatic intraepithelial neoplasia (PanIN)/carcinoma in situ) and stage I 
(invasive carcinoma with tumor diameter of <20 mm confined within the pancreas, along with 
the absence of regional lymph node metastasis (N0) and distant metastasis (M0)). Stage I 
cases were further classified as stage I (TS1a) (tumor size <10 mm) and stage I (TS1b) (tumor 
size 11-20 mm) based on the tumor size in largest diameter [5]. The pathologic assessment of 
cases was left to the discretion of each institution. Concomitant IPMN, in which PDAC 
developed at a site in the pancreas different from that of the IPMN according to the imaging 
and/or histologic findings [10], was regarded as a risk factor. Patients with high-grade IPMN 
or IPMN-derived invasive cancer, showing a histologic transition between IPMN and PDAC, 
were excluded. Some patients included in this study were reported in our previous review in 
Japanese [11]. 
The following information was sent to the data center at Tohoku University Graduate 
School of Medicine after linkable anonymization: (i) clinical backgrounds (age, gender, 
absence or presence of risk factors for PDAC, etc.); (ii) opportunities for medical examination 
for early-stage PDAC (check-up, symptomatic or asymptomatic, incidental detection during 
screening for other diseases); (iii) imaging modalities used for the diagnosis; (iv) imaging 
findings on abdominal ultrasonography (US), computed tomography (CT), magnetic 
 7 
resonance imaging (MRI), endoscopic ultrasonography (EUS), endoscopic retrograde 
cholangiopancreatography (ERCP), and 
18
F-fluorodeoxyglucose-positron emission 
tomography (FDG-PET); (v) the methods for the cytological diagnosis of early-stage PDAC 
(ERCP or EUS-fine needle aspiration (FNA)); and (vi) prognosis. 
All analyses were performed using JMP software (version 9.0.2; SAS Institute, 
Chicago, IL, USA). Continuous variables were compared using Student’s t test. Chi-square 
test or Fisher's exact test was appropriately used for the comparison of proportions. The 
Kaplan–Meier survival analysis was used to compare the overall survival according to the 
stage. This study was approved by the institutional review boards of all participating 
institutions. 
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Results 
Clinical characteristics of early-stage PDAC 
In the 14 participating institutions, 6,942 cases with PDAC were diagnosed and 
2,647 cases underwent resection during the study period. There were 51 stage 0 and 149 
stage I cases accounting for 0.7% and 2.3% of the all PDAC cases, respectively. Of the 200 
cases with stage 0 and I PDAC, there were 109 men and 91 women, with an average age of 
68.8 years (range, 39-88 years). The average observation period was 1240.8 days (range, 
66–3635 days). PDAC was located in the pancreatic head in 86 (43%) cases, in the 
pancreatic body in 103 (51.5%) cases, and in the pancreatic tail in only 11 (5.5%) cases. One 
hundred thirty nine (69.5%) cases had at least one risk factor. DM was present in 64 (32.0%), 
smoking in 62 (31.0%), and IPMN in 52 (26.0%) cases. We only inquired about the presence 
or absence of DM, but did not ask about the interval of DM onset and PDAC diagnosis. The 
clinical characteristics were not different between stage 0 and I cases (data not shown). 
 
Opportunities for detection of early-stage PDAC 
Early-stage PDAC was detected by further medical examination due to the presence 
of symptoms in 50 cases (25.0%): abnormalities on medical check-up in 34 (17.0%) and 
abnormalities during examination or follow-up for other diseases in 103 (51.5%). The 
patients presented with the following symptoms: abdominal pain in 36 (72.0%), back pain in 
13 (26.0%), nausea in 4 (8.0 %), diarrhea in 1 (2.0%), and jaundice in 1 (2.0%). Of the 34 
patients in whom abnormalities were detected during medical check-up, 31 (91.2%) were 
detected by US, whereas only 1 (2.9%) case presented with an elevation of tumor marker 
levels. The abnormal findings detected by US were dilatation of the main pancreatic duct 
(MPD) in 21 (67.7%) cases, direct detection of a tumor in 9 (29.0%), and stenosis of the 
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MPD in 1 (3.2%). Among the 103 patients in whom an abnormality was incidentally 
detected during examination or follow-up for other diseases, 99 (96.1%) cases had abnormal 
imaging findings on CT (n=49; 49.5%) and US (n=41; 41.4%). Cases with elevated 
pancreatic enzyme and tumor marker levels were rare. No stage 0 PDAC case presented with 
elevated tumor markers. 
 
Imaging modalities for diagnosis of early-stage PDAC 
Several imaging modalities were used for the diagnosis of early-stage PDAC; in 
particular, CT, MRI, and EUS were performed in most cases (Table 3). Abnormal US 
findings included MPD dilatation in 101/135 (74.8%) cases, MPD stenosis in 27/135 (20.0%), 
and tumor detection in 71/135 (52.6%). Abnormal CT findings were MPD dilatation in 
156/196 (79.6%) cases, tumor detection in 101/196 (51.5%), and local fatty changes in 82/196 
(41.8%) (Fig. 1). Abnormal MRI findings included MPD dilatation in 143/173 (82.7%) cases 
and tumor detection in 78/173 (45.1%). Abnormal findings on EUS were MPD dilatation in 
153/173 (88.4%) cases, MPD stenosis in 98/173 (56.6%), and tumor detection in 132/173 
(76.3%). ERCP was performed after informed consent in 141 (70.5%) cases and revealed 
MPD dilatation in 114/141 (80.9%) and MPD stenosis in 112/141 (79.4%) cases. FDG-PET 
was performed in 61 (30.5%) cases and FDG accumulation was seen in 1/11 stage 0 and 30/50 
(60.0%) stage I cases. We compared the number of positive imaging findings out of 14 
assessed in this study (MPD dilatation, MPD stenosis, and pancreatic tumors on US; MPD 
dilatation, pancreatic tumors, and local fatty changes of parenchyma on CT; MPD dilatation 
and pancreatic tumors on MRI; MPD dilatation, MPD stenosis, and pancreatic tumors on 
EUS; MPD dilatation and MPD stenosis on ERCP, and FDG accumulation on FDG-PET) 
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between stage 0 and I cases. The number of positive imaging findings was significantly lower 
in stage 0 (5.5±2.5,  mean±standard deviation) cases than in stage I cases (7.2±2.8) (P<0.01).  
Of note, pancreatic tumors were seldom detected by imaging modalities in stage 0 cases. 
 
Cytological diagnosis of early-stage PDAC 
Cytology is important for histologic confirmation of PDAC. Malignancy was 
confirmed by cytology prior to resection in 125 (62.5%) cases. In the remaining 75 (37.5%) 
cases, decision of resection was made after informed consent with high suspicion of PDAC 
based on abnormal imaging findings, especially MPD dilatation on multiple modalities. If 
stratified by stage, 27/51 (52.9%) stage 0 cases and 98/141 (65.8%) stage 1 cases underwent 
resection after the confirmation of malignancy. Most (26/27; 96.3%) of the stage 0 cases 
were diagnosed using pancreatic juice obtained by endoscopic nasopancreatic duct drainage 
(ENPD) and only one case was diagnosed by EUS-FNA (Table 4). Six stage 0 cases were 
also diagnosed by brushing cytology. In the stage 1 cases, 24 were diagnosed by brushing 
cytology, 29 using the pancreatic juice obtained by ENPD, and 53 by EUS-FNA. The 
proportion of malignancy by EUS-FNA was higher in stage 1 (53/63; 84.1%) than in stage 0 
(1/6; 16.7%) (P=0.001).  
 
Prognosis 
Figure 3 shows the Kaplan–Meier estimates of the overall survival according to the 
stages. The estimated overall survival rates at 10 years after the resection for stage 0, stage I 
(TS1a), and stage I (TS1b) were 94.7%, 93.8%, and 78.9%, respectively (Fig. 2). Although 
the difference was not statistically significant, overall survival rates tended to be lower in the 
Stage I (TS1b) cases (P=0.07 vs. stage 0 cases and P=0.20 vs. stage I (TS1a) cases). Of note, 
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new PDAC lesions were detected in the remnant pancreas in 31 cases (15.5%) (Fig. 3). 
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Discussion 
The prognosis of PDAC has not improved despite extensive research and advances in 
imaging modalities. PDAC develops through a stepwise progression from precursor lesions 
including PanIN [12]. PanIN originates in small terminal pancreatic ducts [13]. Using a 
mathematical model, Yachida et al. [14] estimated a period of 11.7 years on average from the 
initiation of pancreatic tumorigenesis until the birth of the founder cell of a parental clone, 
6.8 years until the birth of the cell giving rise to the index lesion, and 2.7 years until the death 
of the patient. Theoretically, there is a chance to diagnose early-stage PDAC, but it is a great 
challenge in daily practice [6, 7]. We here reported the clinical characteristics of 200 patients 
with early-stage PDAC. Only 25% cases were symptomatic, indicating the importance of 
surveillance in asymptomatic subjects. There is a consensus that screening of PDAC should 
be performed within high-risk groups but not within the general population [15, 16]. There 
are several risk factors for PDAC including a family history of pancreatic cancer or 
hereditary pancreatic cancer syndrome, hereditary pancreatitis, DM, obesity, chronic 
pancreatitis, IPMN, pancreatic cysts, smoking, and alcohol consumption [8]. In this study, 
about 70% of the patients had at least one risk factor, with DM as the most common. An 
association between new-onset DM and pancreatic cancer has been established [17], but it 
remains unknown whether new-onset DM is associated with early-stage PDAC. The large 
number of patients with new-onset DM is an obstacle to developing an efficient screening 
system.  
Several reports have described strategies for the surveillance of high-risk groups. 
Canto et al. [15] demonstrated the diagnostic utility of EUS and MRI in high-risk patients 
with hereditary pancreatic cancer syndrome and a family history of PDAC. Harinck et al. 
[18] reported the complementary roles of EUS and MRI in detecting pancreatic lesions in 
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such patients. Kamata et al. [19] reported that semiannual EUS was superior to annual US, 
CT or MRI for detecting concomitant PDAC during the follow-up of patients with IPMN. 
These reports confirm the utility of EUS in detecting PDAC in subjects at high risk. 
However, the number of facilities that can perform EUS routinely is still limited even in 
Japan and multiple EUS sessions per year for all IPMN cases are not realistic in the clinical 
setting.   
 Malignancy was confirmed by cytology prior to resection in 125 (62.5%) cases. 
Unlike PDAC cases in general, EUS-FNA was not useful for the preoperative diagnosis of 
malignancy in stage 0 cases, because the tumor could not be directly detected. Most of the 
stage 0 cases were diagnosed using pancreatic juice obtained by ENPD. Repeated pancreatic 
juice cytology using ENPD revealed that serial pancreatic juice aspiration cytological 
examination could be a feasible method for the diagnosis of pancreatic carcinoma in situ [20]. 
On the other hand, the remaining 75 (37.5%) cases underwent resection despite the absence 
of preoperative confirmation of malignancy. In these cases, the decision for resection was 
made with a high suspicion of PDAC based on abnormal imaging findings. Many imaging 
modalities are utilized during the diagnostic process of early-stage PDAC. Cases with stage 
0 presented with fewer imaging findings than stage I cases, mainly due to the difficulty in the 
actual identification of tumors in stage 0 cases. Our results underscored the importance of 
indirect imaging findings for detecting early-stage PDAC in asymptomatic cases. The 
relatively low proportion of cases in the pancreatic tail (5.5%) might reflect the rarity of 
developing MPD dilatation due to the relatively small volume upstream of the tumor. 
Subjects with the risk factors, especially those with multiple risk factors, should be advised 
to undergo further medical examination if such findings are detected. In addition to MPD 
dilatation, abnormal MPD stenosis was observed on ERCP in 83% of stage 0 cases. 
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Interestingly, local fatty changes of the pancreatic parenchyma were detected in 21/50 (42%) 
stage 0 and 61/146 (41.8%) stage I cases. The underlying mechanism for the development of 
local fatty changes remains unknown, but might involve the interaction with the surrounding 
pancreatic parenchyma [21, 22]. 
 In this study, PDAC developed in the remnant pancreas in 31 (15.5%) cases. 
Along with the previous case reports of metachronous cancer in the remnant pancreas [23, 
24], our results suggested the importance of follow-up after surgery even in patients with 
early-stage PDAC. For the postoperative surveillance, the NCCN Clinical Practice 
Guidelines [25] recommend a history and physical examination for symptom assessment 
every 3 to 6 months for 2 years, then every 6 to 12 months, and then CA 19-9 level testing 
and follow-up contrast-enhanced CT scans every 3 to 6 months for 2 years after surgical 
resection. The Japanese Guidelines [8] suggest tumor marker assessment and follow-up 
contrast-enhanced CT scans every 3 to 6 months for 2 years, then every 6 to 12 months at 
least for 5 years after surgical resection. Because the prognosis of patients with early-stage 
PDAC is much more favorable than the general PDAC cases, cost-effectiveness is another 
important issue for the long-term surveillance after resection [26].  
 In summary, this multicenter study revealed several key points in the diagnosis 
and management of early-stage PDAC, including risk factors, screening of asymptomatic 
cases, identification of indirect imaging findings, and the risk of carcinogenesis in the 
remnant pancreas. Because the number of gastroenterologists specializing in pancreatic 
cancer is rather limited, it is important that these key points be made known to general 
physicians as well and prompt them to refer suspicious cases to core hospitals for further 
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examinations [26]. Further clarification of early-stage PDAC is warranted to improve the 
prognosis of this intractable disease.  
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Figure legends 
Figure 1: A case of stage I PDAC with localized fatty changes 
a. Localized tissue atrophy and fatty changes are observed in the pancreatic tail on CT 
(arrowhead). 
b. Histologic findings reveal fatty changes in localized regions of the pancreatic 
parenchyma. 
c. High-grade PanIN/carcinoma in situ is observed in a branch of the pancreatic duct. 
 
Figure 2: Kaplan–Meier estimates of the overall survival according to the stages. 
The overall survival was calculated using the Kaplan–Meier method. Censored subjects are 
indicated on the Kaplan-Meier curve as tick marks. The overall survival rates at 10 years 
after the resection were 94.7% in stage 0 cases, 93.8% in stage I (TSIa), and 78.9% in stage I 
(TSIb). 
 
Figure 3: A case of newly developed PDAC in the remnant pancreas 
a. CT reveals a small tumor in the pancreatic body (arrow). 
b. The pancreatic tumor is detected by EUS in the pancreatic body (arrow). 
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c. At the age of 61 years, this patient underwent distal pancreatectomy, which revealed 
stage I pancreatic cancer with clear margins on pathologic examination. 
d. After four years, a new tumor was detected in the pancreatic head on CT (arrowhead). 
e. EUS revealed a hypoechoic lesion in the pancreatic head (arrowhead). 
f. This patient underwent total remnant pancreatectomy and the pathologic diagnosis was 
invasive PDAC. 
 
